Want to see AKTS full AI Analyst Report?
Top Page
Aktis Oncology, Inc.
(NASDAQ:AKTS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$15.00
▼(-44.28% Downside)
Action:Reiterated
Date:10/02/26
AKTS scores low primarily due to weak financial fundamentals (large losses, negative and deteriorating equity, and a return to heavy cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation metrics provide limited offset because the company is loss-making and has no dividend yield listed.
Positive Factors
Revenue Expansion
The sharp increase in revenue indicates that the company is progressing beyond an earlier, very small base and generating greater activity from its oncology business. If this expansion persists, it could improve operating leverage and provide a broader foundation for funding future development.
Negative Factors
Severe Unprofitability
The scale of losses relative to revenue shows that Aktis is still operating far from breakeven and remains in an intensive investment phase. Persistent operating losses can consume capital faster than the business generates it, making future progress increasingly dependent on financing or substantial earnings improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
The sharp increase in revenue indicates that the company is progressing beyond an earlier, very small base and generating greater activity from its oncology business. If this expansion persists, it could improve operating leverage and provide a broader foundation for funding future development.
Read all positive factors
Aktis Oncology, Inc. (AKTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$874.89M
Dividend YieldN/A
Average Volume (3M)466.35K
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees79
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,746,670
10 Day Avg. Volume380,301
30 Day Avg. Volume466,350
Financial Highlights & Ratios
PEG Ratio3.39
Price to Book (P/B)-8.05
Price to Sales (P/S)181.08
P/FCF Ratio-15.96
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue126.92
Enterprise Value/Gross Profit149.71
Enterprise Value/Ebitda-16.42
Forecast
1Y Price Target
$35.80Price Target Upside32.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aktis Oncology, Inc. Business Overview & Revenue Model
Company Description
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the disc...
Aktis Oncology, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.06M | 6.50M | 1.49M | 0.00 | 0.00 |
| Gross Profit | 8.53M | 6.50M | 1.49M | 0.00 | 0.00 |
| EBITDA | -77.74M | -61.40M | -42.41M | -27.52M | -17.48M |
| Net Income | -73.14M | -63.73M | -43.98M | -28.64M | -17.93M |
Balance Sheet | |||||
| Total Assets | 557.60M | 264.88M | 326.18M | 122.36M | 138.32M |
| Cash, Cash Equivalents and Short-Term Investments | 517.32M | 226.79M | 297.17M | 97.86M | 128.60M |
| Total Debt | 11.24M | 11.55M | 12.01M | 13.40M | 1.77M |
| Total Liabilities | 72.76M | 411.03M | 413.98M | 168.66M | 157.55M |
| Stockholders Equity | 484.84M | -146.15M | -87.80M | -46.31M | -19.23M |
Cash Flow | |||||
| Free Cash Flow | -84.57M | -73.71M | 11.90M | -33.77M | -20.43M |
| Operating Cash Flow | -75.29M | -64.13M | 14.76M | -30.00M | -18.13M |
| Investing Cash Flow | -289.39M | 65.96M | -190.40M | -68.83M | -2.31M |
| Financing Cash Flow | 336.96M | -1.21M | 183.28M | 0.00 | 119.98M |
Aktis Oncology, Inc. Risk Analysis
Aktis Oncology, Inc. disclosed 94 risk factors in its most recent earnings report. Aktis Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aktis Oncology, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.38B | -19.30 | -40.51% | ― | 34.52% | 41.20% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $2.02B | -13.97 | -72.07% | ― | -69.78% | -106.07% | |
54 Neutral | $1.60B | -171.82 | -2.35% | ― | 20.19% | ― | |
44 Neutral | $1.37B | -9.76 | -35.35% | ― | ― | 28.64% | |
42 Neutral | $874.89M | -14.98 | -41.07% | ― | ― | ― | |
42 Neutral | $1.47B | -23.44 | 89.71% | ― | ― | ― |
* General Sector Average
AKTS
Aktis Oncology, Inc.
15.73
-6.67
-29.78%
IOVA
Iovance Biotherapeutics
13.78
11.47
496.54%
ZYME
Zymeworks
28.37
9.90
53.60%
ORIC
Oric Pharmaceuticals
8.96
-4.45
-33.17%
IMCR
Immunocore Holdings
31.28
-2.18
-6.52%
NBTX
Nanobiotix
31.53
16.45
109.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.